EquitySector - HealthcareVery High Risk
Regular
NAV (17-Apr-25)
Returns (Since Inception)
Fund Size
₹1,042 Cr
Expense Ratio
2.25%
ISIN
INF789F01695
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
28 Jun 1999
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+20.92%
+17.55% (Cat Avg.)
3 Years
+19.03%
+18.10% (Cat Avg.)
5 Years
+22.37%
+22.46% (Cat Avg.)
10 Years
+10.51%
+12.75% (Cat Avg.)
Since Inception
+14.83%
— (Cat Avg.)
Equity | ₹1,033.76 Cr | 99.21% |
Others | ₹8.28 Cr | 0.79% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹121.43 Cr | 11.65% |
Cipla Ltd | Equity | ₹60.57 Cr | 5.81% |
Ajanta Pharma Ltd | Equity | ₹45.87 Cr | 4.40% |
Dr Reddy's Laboratories Ltd | Equity | ₹45.31 Cr | 4.35% |
Glenmark Pharmaceuticals Ltd | Equity | ₹42.42 Cr | 4.07% |
Procter & Gamble Health Ltd | Equity | ₹38.08 Cr | 3.65% |
Apollo Hospitals Enterprise Ltd | Equity | ₹37.23 Cr | 3.57% |
Fortis Healthcare Ltd | Equity | ₹32.47 Cr | 3.12% |
Divi's Laboratories Ltd | Equity | ₹32.34 Cr | 3.10% |
Alkem Laboratories Ltd | Equity | ₹31.16 Cr | 2.99% |
Suven Pharmaceuticals Ltd | Equity | ₹30.91 Cr | 2.97% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹30.7 Cr | 2.95% |
Eris Lifesciences Ltd Registered Shs | Equity | ₹30.18 Cr | 2.90% |
Aurobindo Pharma Ltd | Equity | ₹29.01 Cr | 2.78% |
Gland Pharma Ltd | Equity | ₹28.66 Cr | 2.75% |
Caplin Point Laboratories Ltd | Equity | ₹24.46 Cr | 2.35% |
Lupin Ltd | Equity | ₹24.34 Cr | 2.34% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹23.66 Cr | 2.27% |
Zydus Lifesciences Ltd | Equity | ₹22.15 Cr | 2.13% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹20.94 Cr | 2.01% |
Global Health Ltd | Equity | ₹19.85 Cr | 1.91% |
Torrent Pharmaceuticals Ltd | Equity | ₹19.12 Cr | 1.83% |
Jupiter Life Line Hospitals Ltd | Equity | ₹17.88 Cr | 1.72% |
Windlas Biotech Ltd | Equity | ₹15.97 Cr | 1.53% |
Metropolis Healthcare Ltd | Equity | ₹15.65 Cr | 1.50% |
Marksans Pharma Ltd | Equity | ₹15.31 Cr | 1.47% |
Sequent Scientific Ltd | Equity | ₹14.18 Cr | 1.36% |
Vijaya Diagnostic Centre Ltd | Equity | ₹14.1 Cr | 1.35% |
Sai Life Sciences Ltd | Equity | ₹14.02 Cr | 1.35% |
Pfizer Ltd | Equity | ₹13.83 Cr | 1.33% |
Syngene International Ltd | Equity | ₹13.07 Cr | 1.25% |
Ipca Laboratories Ltd | Equity | ₹12.77 Cr | 1.23% |
Alembic Pharmaceuticals Ltd | Equity | ₹12.75 Cr | 1.22% |
Emcure Pharmaceuticals Ltd | Equity | ₹12.33 Cr | 1.18% |
Ami Organics Ltd | Equity | ₹12.27 Cr | 1.18% |
Sanofi Consumer Healthcare India Ltd | Equity | ₹11.48 Cr | 1.10% |
Laxmi Dental Ltd | Equity | ₹10.91 Cr | 1.05% |
Net Current Assets | Cash | ₹8.14 Cr | 0.78% |
Rainbow Childrens Medicare Ltd | Equity | ₹8.14 Cr | 0.78% |
Jubilant Pharmova Ltd | Equity | ₹8.03 Cr | 0.77% |
Poly Medicure Ltd | Equity | ₹6.29 Cr | 0.60% |
Concord Biotech Ltd | Equity | ₹5.88 Cr | 0.56% |
Orchid Pharma Ltd | Equity | ₹4.28 Cr | 0.41% |
Indegene Ltd | Equity | ₹3.74 Cr | 0.36% |
Clearing Corporation Of India Ltd. Std - Margin | Cash - Repurchase Agreement | ₹0.14 Cr | 0.01% |
Large Cap Stocks
28.88%
Mid Cap Stocks
27.76%
Small Cap Stocks
41.52%
AAA
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹1,021.49 Cr | 98.03% |
Basic Materials | ₹12.27 Cr | 1.18% |
Standard Deviation
This fund
16.70%
Cat. avg.
16.77%
Lower the better
Sharpe Ratio
This fund
0.78
Cat. avg.
0.75
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.30
Higher the better
Since May 2022
ISIN INF789F01695 | Expense Ratio 2.25% | Exit Load 1.00% | Fund Size ₹1,042 Cr | Age 25 years 9 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Bajaj Finserv Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹307.40 Cr | - |
Bajaj Finserv Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹307.40 Cr | - |
PGIM India Healthcare Fund Direct Growth Very High Risk | 0.7% | 0.0% | ₹104.18 Cr | - |
PGIM India Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹104.18 Cr | - |
WhiteOak Capital Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹303.62 Cr | 26.8% |
WhiteOak Capital Pharma and Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹303.62 Cr | 29.0% |
DSP Nifty Healthcare ETF Regular Growth Very High Risk | 0.2% | - | ₹9.77 Cr | 15.8% |
Kotak Healthcare Fund Direct Growth Very High Risk | 0.8% | 0.0% | ₹411.54 Cr | 16.3% |
Kotak Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹411.54 Cr | 14.4% |
HDFC Pharma and Healthcare Fund Regular Growth Very High Risk | 2.1% | 1.0% | ₹1634.08 Cr | 27.7% |
Total AUM
₹3,03,409 Cr
Address
UTI Towers, Gn Block, Mumbai, 400 051
Your principal amount will be at Very High Risk
EquitySector - HealthcareVery High Risk
Regular
NAV (17-Apr-25)
Returns (Since Inception)
Fund Size
₹1,042 Cr
Expense Ratio
2.25%
ISIN
INF789F01695
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
28 Jun 1999
Your principal amount will be at Very High Risk
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+20.92%
+17.55% (Cat Avg.)
3 Years
+19.03%
+18.10% (Cat Avg.)
5 Years
+22.37%
+22.46% (Cat Avg.)
10 Years
+10.51%
+12.75% (Cat Avg.)
Since Inception
+14.83%
— (Cat Avg.)
Equity | ₹1,033.76 Cr | 99.21% |
Others | ₹8.28 Cr | 0.79% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹121.43 Cr | 11.65% |
Cipla Ltd | Equity | ₹60.57 Cr | 5.81% |
Ajanta Pharma Ltd | Equity | ₹45.87 Cr | 4.40% |
Dr Reddy's Laboratories Ltd | Equity | ₹45.31 Cr | 4.35% |
Glenmark Pharmaceuticals Ltd | Equity | ₹42.42 Cr | 4.07% |
Procter & Gamble Health Ltd | Equity | ₹38.08 Cr | 3.65% |
Apollo Hospitals Enterprise Ltd | Equity | ₹37.23 Cr | 3.57% |
Fortis Healthcare Ltd | Equity | ₹32.47 Cr | 3.12% |
Divi's Laboratories Ltd | Equity | ₹32.34 Cr | 3.10% |
Alkem Laboratories Ltd | Equity | ₹31.16 Cr | 2.99% |
Suven Pharmaceuticals Ltd | Equity | ₹30.91 Cr | 2.97% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹30.7 Cr | 2.95% |
Eris Lifesciences Ltd Registered Shs | Equity | ₹30.18 Cr | 2.90% |
Aurobindo Pharma Ltd | Equity | ₹29.01 Cr | 2.78% |
Gland Pharma Ltd | Equity | ₹28.66 Cr | 2.75% |
Caplin Point Laboratories Ltd | Equity | ₹24.46 Cr | 2.35% |
Lupin Ltd | Equity | ₹24.34 Cr | 2.34% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹23.66 Cr | 2.27% |
Zydus Lifesciences Ltd | Equity | ₹22.15 Cr | 2.13% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹20.94 Cr | 2.01% |
Global Health Ltd | Equity | ₹19.85 Cr | 1.91% |
Torrent Pharmaceuticals Ltd | Equity | ₹19.12 Cr | 1.83% |
Jupiter Life Line Hospitals Ltd | Equity | ₹17.88 Cr | 1.72% |
Windlas Biotech Ltd | Equity | ₹15.97 Cr | 1.53% |
Metropolis Healthcare Ltd | Equity | ₹15.65 Cr | 1.50% |
Marksans Pharma Ltd | Equity | ₹15.31 Cr | 1.47% |
Sequent Scientific Ltd | Equity | ₹14.18 Cr | 1.36% |
Vijaya Diagnostic Centre Ltd | Equity | ₹14.1 Cr | 1.35% |
Sai Life Sciences Ltd | Equity | ₹14.02 Cr | 1.35% |
Pfizer Ltd | Equity | ₹13.83 Cr | 1.33% |
Syngene International Ltd | Equity | ₹13.07 Cr | 1.25% |
Ipca Laboratories Ltd | Equity | ₹12.77 Cr | 1.23% |
Alembic Pharmaceuticals Ltd | Equity | ₹12.75 Cr | 1.22% |
Emcure Pharmaceuticals Ltd | Equity | ₹12.33 Cr | 1.18% |
Ami Organics Ltd | Equity | ₹12.27 Cr | 1.18% |
Sanofi Consumer Healthcare India Ltd | Equity | ₹11.48 Cr | 1.10% |
Laxmi Dental Ltd | Equity | ₹10.91 Cr | 1.05% |
Net Current Assets | Cash | ₹8.14 Cr | 0.78% |
Rainbow Childrens Medicare Ltd | Equity | ₹8.14 Cr | 0.78% |
Jubilant Pharmova Ltd | Equity | ₹8.03 Cr | 0.77% |
Poly Medicure Ltd | Equity | ₹6.29 Cr | 0.60% |
Concord Biotech Ltd | Equity | ₹5.88 Cr | 0.56% |
Orchid Pharma Ltd | Equity | ₹4.28 Cr | 0.41% |
Indegene Ltd | Equity | ₹3.74 Cr | 0.36% |
Clearing Corporation Of India Ltd. Std - Margin | Cash - Repurchase Agreement | ₹0.14 Cr | 0.01% |
Large Cap Stocks
28.88%
Mid Cap Stocks
27.76%
Small Cap Stocks
41.52%
AAA
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹1,021.49 Cr | 98.03% |
Basic Materials | ₹12.27 Cr | 1.18% |
Standard Deviation
This fund
16.70%
Cat. avg.
16.77%
Lower the better
Sharpe Ratio
This fund
0.78
Cat. avg.
0.75
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.30
Higher the better
Since May 2022
ISIN INF789F01695 | Expense Ratio 2.25% | Exit Load 1.00% | Fund Size ₹1,042 Cr | Age 25 years 9 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Bajaj Finserv Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹307.40 Cr | - |
Bajaj Finserv Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹307.40 Cr | - |
PGIM India Healthcare Fund Direct Growth Very High Risk | 0.7% | 0.0% | ₹104.18 Cr | - |
PGIM India Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹104.18 Cr | - |
WhiteOak Capital Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹303.62 Cr | 26.8% |
WhiteOak Capital Pharma and Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹303.62 Cr | 29.0% |
DSP Nifty Healthcare ETF Regular Growth Very High Risk | 0.2% | - | ₹9.77 Cr | 15.8% |
Kotak Healthcare Fund Direct Growth Very High Risk | 0.8% | 0.0% | ₹411.54 Cr | 16.3% |
Kotak Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹411.54 Cr | 14.4% |
HDFC Pharma and Healthcare Fund Regular Growth Very High Risk | 2.1% | 1.0% | ₹1634.08 Cr | 27.7% |
Total AUM
₹3,03,409 Cr
Address
UTI Towers, Gn Block, Mumbai, 400 051
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments